Italy probes Biogen for allegedly hindering sales of rival's MS drug

Italy's antitrust regulator has opened an investigation into Biogen over allegations it used its Stratify anti-JCV test to hinder Sandoz's lower-cost MS biosimilar Tyruko and tie testing to sales of Tysabri. The watchdog says Sandoz's drug could cost at least 20% less, implying potential savings to Italy's health system if competition is restored. The case adds regulatory and legal overhang for Biogen, though it is still an investigation rather than a formal ruling.

Analysis

This is less about a single Italian market and more about a repeatable antitrust pattern in specialty pharma: if the test gatekeeping theory sticks, the regulatory risk migrates from product-level pricing to platform-level control. That matters because diagnostics-linked exclusivity can preserve share far longer than patent life would normally justify, but once challenged it tends to be judged harshly by EU authorities, making the downside asymmetrically legal rather than operational.

The immediate loser is BIIB, but the second-order beneficiary is any European biosimilar manufacturer with interchangeable or hospital-channel penetration, because procurement teams will use the case to pressure originators across other natalizumab-like workflows. Even if Biogen ultimately prevails, the investigation itself can push hospital tendering behavior and physician protocols toward “test portability,” which erodes switching costs and compresses gross-to-net over the next 6-18 months.

The bigger risk is not a fine; it is forced remediation that could require commercial availability of the test independent of Tysabri access or a formal separation of diagnostics from drug purchase. That would reduce Biogen’s ability to defend the franchise in Europe, and could also embolden regulators in adjacent therapeutic areas where monitoring tests are used as de facto exclusion tools. A clean reversal likely needs either a narrow procedural finding or a settlement that preserves the current commercial architecture, which is less likely once the regulator frames this as health-system savings and competition policy.

Consensus may be underpricing the signaling effect to Brussels and other national authorities: even a mid-sized EU case can trigger copycat complaints if hospital buyers see a path to reclaim 20%+ in spend. For holders of BIIB, the core issue is not earnings math today but a creeping multiple discount tied to litigation/regulatory uncertainty in ex-US markets. The market often waits for quantified fines; in these cases, the real P&L hit usually comes earlier through tender delays and slower biosimilar uptake.

Key Decisions for Investors

• Short BIIB on any strength over the next 1-2 weeks; use the investigation headline as a tactical entry with a 3-6 month horizon, targeting downside from a rising EU antitrust discount rather than near-term EPS revisions.
• For event-driven exposure, buy BIIB put spreads 3-6 months out to express regulatory downside while capping theta; structure around strikes just below current implied move to monetize any settlement or adverse interim findings.
• Pair trade: long European biosimilar basket / short BIIB for a 6-12 month regulatory convergence trade, as hospital-channel enforcement risk should favor lower-cost competitors if diagnostics access is compelled to decouple.
• Avoid adding to BIIB until there is clarity on whether the AGCM is pursuing behavioral remedies; a remedies-driven outcome would likely be more damaging than a one-time fine because it alters franchise economics for years.